You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The approval will allow clinicians to identify NSCLC patients with ROS1 fusion genes who could benefit from treatment with Rozlytrek.
Companies developing tests for cancer therapy selection, therapy monitoring, and screening received most of the private investment, funding experts said.
As part of the distribution agreement, Biolidics will distribute the IncellDx bioINK kit with Biolidics' ClearCell FX1 system.
Cytek said the reagents consist of basic T, B, and NK cell cluster of differentiation markers used for lymphocyte subset detection.
The firm has entered the market in Africa with a new collaboration in Ghana. It is also developing instrument-agnostic STI and liquid biopsy tests.
The Australian company also plans to offer 72 million new shares to eligible existing shareholders to raise additional funds.
The clearance covers tests made by the firm's joint venture for manufacturing, CoSara Diagnostics, in its facility in Ranoli, India.
The Genetron Health S5 NGS system is based on the Thermo Fisher Scientific Ion GeneStudio S5 and will be accompanied by Genetron-developed assays.
The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.
The financing will go toward building out its sales teams in the US and Europe in order to market its multiplexed MDx tests for infectious diseases.